|- candidate number||14940|
|- NTR Number||NTR4012|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||31-mei-2013|
|- Secondary IDs||NL42401.041.12. METC|
|- Public Title||Combination of locally administered radiotherapy and thermal tumour destruction for treatment of liver metastases originated from primary bowel cancer |
|- Scientific Title||Radioembolization for Colorectal Liver Metastases after Ablation: a Prospective study|
|- ACRONYM||The RELAPSE study|
|- hypothesis||By combining Yttrium-90 radioembolization and Radiofrequency Ablation for treatment of patients with colorectal liver metastases, we might be able to target the remnant tumour cells in the rim of the ablation zone and improve the disease free survival of the patients. |
|- Healt Condition(s) or Problem(s) studied||Colorectal metastised cancer, Recurrent , Radiofrequency ablation, Radio embolization|
|- Inclusion criteria||1.Patients who have signed written informed consent;|
2.Patients undergoing open, laparoscopic or percutaneous RFA treatment;
3.Aged 18 years or older;
4.ECOG performance status of 0-2;
5.Subjects with at least one and a maximum of five measurable lesion according to the RECIST criteria (5.0 cm or smaller in axial plane) on pre-operative imaging;
6.Normal renal and liver function tests at baseline (as described above).
|- Exclusion criteria||1.Irresectable extrahepatic metastases;|
3.Pregnant or breast-feeding patients;
4.Any form of chemotherapy within 2 months prior to the Y-90 radioembolization;
5.Exclusion criteria of radioembolization:
- Compromised main portal vein;
- Uncorrectable extrahepatic shunting to the gastrointestinal tract;
- Unacceptable shunting to the lungs.
|- mec approval received||no|
|- multicenter trial||yes|
|- Type||Single arm|
|- planned startdate ||1-sep-2013|
|- planned closingdate||1-sep-2015|
|- Target number of participants||50|
|- Interventions||The standard treatment is Radiofrequency Ablation (RFA) for colorectal liver metastases (CRLM). Patients will not be randomized. All patients will additionally be treated with Yttirum-90 Radioembolization, one month after the RFA procedure. The RFA procedure can be performed percutaneously, laparoscopically or during an open procedure. The duration of the RFA procedure depends on the surgical approach and the number of the lesions. One or two weeks prior to the radioembolization procedure, each patient will undergo pre-procedural screening by means of hepatic angiography and subsequently technetium-99m-labelled albumin macroaggregates (99mTc-MAA) injection, followed by planar imaging and Single Photon Emission Computed Tomography (SPECT). The pre-procedural angiography permits visualization of the anatomy of the vessels and provides an opportunity to embolize arteries if necessary (to spare the gastric and duodenal arterial flow from incorporating radioactive spheres). The 99mTc-MAA and the subsequent nuclear imaging will determine the presence of any shunts from the hepatic arterial system to the pulmonary or gastrointestinal venous systems. Both the pre-procedural screening and the radioembolization procedure will take about 2 tot 3 hours depending on the hepatic vascular anatomy. Patients will be admitted the day before the procedure and discharged the day after the procedure.
The main study parameter is the local liver recurrence rate after RFA combined with Yttrium-90 radioembolization for patients with CRLM. This will be assessed by the number and percentage of patients with local liver recurrence, 12 months after the RFA procedure. Local liver recurrence is defined as: radiologic detection of residual or recurrent viable tumor which is related to the ablation zone, located in the same segment as the treated lesion.|
|- Primary outcome||Local Liver Recurrence Rate (defined as radiologic detection of residual or recurrent viable tumor which is related to the ablation zone, located in the same segment as the treated lesion)|
|- Secondary outcome||Treatment related adverse events|
|- Timepoints||The local liver recurrence and the intrahepatic recurrence rate rate will be assessed 12 months after the RFA procedure.|
Treatment related adverse events will be assessed by the percentage of adverse events occurring within 30 days after the radioembolization procedure.
|- Trial web site||N/A|
|- CONTACT FOR PUBLIC QUERIES||Miss M. Samim|
|- CONTACT for SCIENTIFIC QUERIES||MD. PhD. R. Hillegersberg, van|
|- Sponsor/Initiator ||University Medical Center Utrecht (UMCU), Department of Surgery|
(Source(s) of Monetary or Material Support)
|University Medical Center Utrecht (UMCU), Department of Surgery |
|- Brief summary||Radiofrequency ablation (RFA) permits an alternative treatment option for patients with irresectable colorectal liver metastases (CRLM). However, local liver recurrence is a frequent phenomenon, which jeopardizes disease free survival (DFS) of these patients. The rate of liver recurrence confined to the liver is up to 60%1, whereas after liver surgery, liver only recurrence is reported in approximately 30 to 35% of patients 2, 3. Experimental data demonstrated a stimulating effect of RFA on the outgrowth of remaining tumor cells surrounding the lesion4. Selective internal Yttrium-90 (Y-90) radioembolization is a form of brachytherapy in which radioactive microspheres are injected into the hepatic artery in order to destroy malignant tissue. A combination therapy of RFA and radioembolization may therefore reduce the local liver recurrence rate and prolong DFS in patients with CRLM. In this study we will assess the feasibility of this approach in patients with CRLM treated with Y-90 radioembolization after RFA.|
Objectives: Primary objective is to assess the efficacy of RFA in combination with Y-90 radioembolization in patients with CRLM.
Secondary objectives are: assessment of occurrence of any treatment related adverse events following RFA in combination with Y-90 radioembolization in patients with CRLM and intrahepatic recurrences within 12 months after the RFA procedure.
Study design: Multicenter, phase II prospective cohort study.
Study population: Patients ¡Ý 18 years of age with CRLM, who previously received potentially curative surgery of the primary tumor (R0) and will undergo radiofrequency ablation for treatment of colorectal liver metastases with a maximum diameter of 5 cm and maximum number of 5 lesions.
Intervention: Patients will undergo RFA followed by Y-90 radioembolization. To allow for liver regeneration, radioembolization will take place one month after the RFA procedure.
Main study parameters/endpoints: Primary endpoint of the study is the local liver recurrence rate after 12 months of follow-up (the local liver recurrence). Secondary endpoints are the occurrence of any treatment related adverse event within 30 days after the Y-90 radioembolization procedure and intrahepatic recurrences.
|- Main changes (audit trail)|
|- RECORD||31-mei-2013 - 14-jun-2013|